p38β (MAPK11) mediates gemcitabine-associated radiosensitivity in sarcoma experimental models.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Gemcitabine is an anticancer drug with radiosensitizing properties.
• The p38 mitogen-activated protein kinase (MAPK) pathway influences cellular response to gemcitabine.
• The precise mechanism of gemcitabine's radiosensitizing effect is not fully understood.

Purpose of the Study:

• To investigate the role of the p38MAPK signaling pathway in gemcitabine-induced radiosensitivity.
• To identify specific p38MAPK isoforms involved in this process.

Main Methods:

• Utilized human and mouse sarcoma cell lines.
• Modulated p38MAPK activity using pharmacological inhibitors and genetic knockdown (shRNAs).
• Assessed cell viability, gene expression, apoptosis, and radiation response using MTT assays, western blot, RT-qPCR, and clonogenic assays.

Main Results:

• Inhibiting the p38MAPK pathway abolished gemcitabine's radiosensitizing effect.
• Knockdown of MAPK14 (p38α) increased gemcitabine resistance but did not alter radiosensitivity.
• Specific knockdown of MAPK11 (p38β) completely eliminated gemcitabine's radiosensitizing potential and increased drug resistance.

Conclusions:

• p38β is identified as a critical mediator of gemcitabine's radiosensitizing effects.
• p38α is not implicated in gemcitabine's radiosensitivity.
• p38β status should be considered when combining gemcitabine with ionizing radiation in cancer therapy.